FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2554001512> ?p ?o ?g. }

• W2554001512 abstract "Abstract Patients with advanced chronic myeloid leukemia (CML) in accelerate (AC) or blastic phase (BC) have a dismal prognosis despite the use of tyrosine kinase inhibitors (TKI). Here we report our experience for allogeneic stem cell transplantation (ASCT) in advanced and phase of CML. Between July 1990 and May 2012 88 patients with a median age of 36 years (range 7-76) received allogeneic stem cell transplantation from related (n=34) or unrelated (n=54) donors , including 19 HLA-mismatched donors after myeloablative (n=54) or reduced intensity (n= 34) conditioning. Stem cell source was bone marrow (n=37) or peripheral blood stem cells (n=51). GvHD prophylaxis consisted of calcineurin inhibitor plus short course MTX or MMF. Most of the patient received additional ATG as GvHD prophylaxis (84%).The majority of patient (75%) received TKIs before ASCT. 50% received one TKI, 8 received 2 TKIs and 2 received 3 TKI before ASCT. At time of transplantation 34 patient achieved a second or subsequent chronic phase, 28 were in accelerate and 25 in blastic phase. Overall the median number of blasts at time of ASCT was 18.75% (range 5-58%) and the time from diagnosis to transplantation was 27 months (range 3-296). No primary graft failure was observed. The incidence of acute graft versus host disease (GvHD) grade II to IV was 43% and of severe grade III/IV GvHD was 28%. Forty-two percent of the patient experienced chronic GvHD. The non-relapse mortality (NRM) at 1 and 5 years was 22% (95% CI; 14-30%) and 23% (95%CI: 13-33%), respectively. In a multivariate analysis (MVA) only higher number of transplanted CD34+ cells were associated with a lower risk of NRM (HR 0.850, 95%CI: 0.729-0.992, p=0.04). The cumulative incidence of relapse at 5 years was 43% (95% CI: 31-55%). In a MVA age > 40 years (HR 2.272, 95%CI: 1.112-4.645, p=0.024) and Reduced intensity conditioning (HR 2.034, 95%CI: 0.998-4.144, p=0.051) were significant factors for higher risk of relapse. After a median follow-up of 91 months (r., 52-133) the estimated 5 and 10 year overall survival was 44% (95% CI: 32-56) and 40% (95% CI: 28-52%), respectively. In an univariate analysis overall survival was significantly influenced by stem cell source, gender, CD34 transplanted cell number and blastic phase at time of transplantation. However, the only significant factor for improved survival in a MVA was a higher number of transplanted CD34+ cells (HR 0.916, 95%CI: 0.844-0.916, p=0.038). Disclosures No relevant conflicts of interest to declare." @default.
• W2554001512 created "2016-11-30" @default.
• W2554001512 creator A5001646221 @default.
• W2554001512 creator A5002853101 @default.
• W2554001512 creator A5017637135 @default.
• W2554001512 creator A5030235127 @default.
• W2554001512 creator A5063350015 @default.
• W2554001512 creator A5070188546 @default.
• W2554001512 creator A5071316542 @default.
• W2554001512 creator A5082862253 @default.
• W2554001512 creator A5086717501 @default.
• W2554001512 creator A5089735033 @default.
• W2554001512 date "2014-12-06" @default.
• W2554001512 modified "2023-09-28" @default.
• W2554001512 title "Allogeneic Stem Cell Transplantation for CML in Accelerate or Blastic Phase" @default.
• W2554001512 doi "https://doi.org/10.1182/blood.v124.21.1220.1220" @default.
• W2554001512 hasPublicationYear "2014" @default.
• W2554001512 type Work @default.
• W2554001512 sameAs 2554001512 @default.
• W2554001512 citedByCount "1" @default.
• W2554001512 countsByYear W25540015122019 @default.
• W2554001512 crossrefType "journal-article" @default.
• W2554001512 hasAuthorship W2554001512A5001646221 @default.
• W2554001512 hasAuthorship W2554001512A5002853101 @default.
• W2554001512 hasAuthorship W2554001512A5017637135 @default.
• W2554001512 hasAuthorship W2554001512A5030235127 @default.
• W2554001512 hasAuthorship W2554001512A5063350015 @default.
• W2554001512 hasAuthorship W2554001512A5070188546 @default.
• W2554001512 hasAuthorship W2554001512A5071316542 @default.
• W2554001512 hasAuthorship W2554001512A5082862253 @default.
• W2554001512 hasAuthorship W2554001512A5086717501 @default.
• W2554001512 hasAuthorship W2554001512A5089735033 @default.
• W2554001512 hasConcept C126322002 @default.
• W2554001512 hasConcept C141071460 @default.
• W2554001512 hasConcept C143998085 @default.
• W2554001512 hasConcept C2777408962 @default.
• W2554001512 hasConcept C2779972918 @default.
• W2554001512 hasConcept C2780611847 @default.
• W2554001512 hasConcept C28328180 @default.
• W2554001512 hasConcept C2911091166 @default.
• W2554001512 hasConcept C54355233 @default.
• W2554001512 hasConcept C71924100 @default.
• W2554001512 hasConcept C86803240 @default.
• W2554001512 hasConcept C90924648 @default.
• W2554001512 hasConceptScore W2554001512C126322002 @default.
• W2554001512 hasConceptScore W2554001512C141071460 @default.
• W2554001512 hasConceptScore W2554001512C143998085 @default.
• W2554001512 hasConceptScore W2554001512C2777408962 @default.
• W2554001512 hasConceptScore W2554001512C2779972918 @default.
• W2554001512 hasConceptScore W2554001512C2780611847 @default.
• W2554001512 hasConceptScore W2554001512C28328180 @default.
• W2554001512 hasConceptScore W2554001512C2911091166 @default.
• W2554001512 hasConceptScore W2554001512C54355233 @default.
• W2554001512 hasConceptScore W2554001512C71924100 @default.
• W2554001512 hasConceptScore W2554001512C86803240 @default.
• W2554001512 hasConceptScore W2554001512C90924648 @default.
• W2554001512 hasLocation W25540015121 @default.
• W2554001512 hasOpenAccess W2554001512 @default.
• W2554001512 hasPrimaryLocation W25540015121 @default.
• W2554001512 hasRelatedWork W1970070684 @default.
• W2554001512 hasRelatedWork W2039015262 @default.
• W2554001512 hasRelatedWork W2111088274 @default.
• W2554001512 hasRelatedWork W2134735812 @default.
• W2554001512 hasRelatedWork W2369520970 @default.
• W2554001512 hasRelatedWork W2423160877 @default.
• W2554001512 hasRelatedWork W2552185487 @default.
• W2554001512 hasRelatedWork W2571119330 @default.
• W2554001512 hasRelatedWork W2581469447 @default.
• W2554001512 hasRelatedWork W2583752009 @default.
• W2554001512 hasRelatedWork W2584739249 @default.
• W2554001512 hasRelatedWork W2587918547 @default.
• W2554001512 hasRelatedWork W2592111748 @default.
• W2554001512 hasRelatedWork W2593267567 @default.
• W2554001512 hasRelatedWork W2594747812 @default.
• W2554001512 hasRelatedWork W2922414381 @default.
• W2554001512 hasRelatedWork W2945103886 @default.
• W2554001512 hasRelatedWork W2977246616 @default.
• W2554001512 hasRelatedWork W2979390620 @default.
• W2554001512 hasRelatedWork W2983147643 @default.
• W2554001512 isParatext "false" @default.
• W2554001512 isRetracted "false" @default.
• W2554001512 magId "2554001512" @default.
• W2554001512 workType "article" @default.